Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 7/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606716 | 0.92 | NAMPT (0.54) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL2132251 | 0.91 | ABCB1 (0.56) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL2606718 | 0.88 | ABCB1 (0.55) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL2828638 | 0.87 | NAMPT (0.61) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL8292317 | 0.85 | HDAC1 (0.56) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL25215311 | 0.84 | ABCB1 (0.47) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL30474768 | 0.84 | ABCB1 (0.47) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL14155935 | 0.82 | CYP2E1 (0.48) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL14155934 | 0.82 | CYP2A6 (0.48) | ABCB1NAMPTMKNK1MKNK2HDAC1 | |
| SCHEMBL2132109 | 0.82 | CD274 (0.51) | ABCB1NAMPTHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2367599-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | Massachusetts Institute of Technology (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065117-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065117-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | ABCB1 4847/4885NAMPT 1233/4885MKNK1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.